Over the past few days there's been a remarkable confluence of newsflow, most of it positive, out of biopharma. First the bad news.    Read More

After a long delay, Eli Lilly finally launched its new bloodthinner Effient just this month. But analysts are already buzzing about what's next.    Read More

Big money managers can instill confidence in individual stocks and you may be able to profit off their moves. Karen Finerman breaks down the holdings of the major money managers.   Read More

Everyone’s talking about the July stock market rally. And, of course, you can’t overlook the outperformance of biotech—big and small.    Read More

For years now, but especially in recent months, I've been covering the obesity epidemic. I regularly report on the statistics and the experimental drug data, detached and "objective" as I think any good reporter should be. It just didn't occur to me that the target population might include my sister.   Read More

Shares of the French drugmaker are getting pummeled over at least three analyst reports identifying a leak about a study or studies that could go public soon. Their research suggests the data is related to a suspected or "theoretical" higher cancer risk associated with SNY's Lantus.    Read More

For people struggling with diabetes, the bathroom scale can be the enemy. But new developments may change that and more!   Read More

"It's a risky business." I don't think I'll ever forget when a Chief Financial Officer said that at an investor conference last year in lieu of reading the whole boring boilerplate "Safe Harbor Statement."    Read More

In less than two weeks, there've been four pretty significant events in biopharma. And, hopefully, after ADA things will begin to settle down a bit for the summer.    Read More

Before I give you the high-tension, high-drama, high-intrigue details of the Biogen Idec shareholder meeting, it's best to just right from the get-go to let you know a spokesperson for the biotech company said, "No comment," about what's going down.    Read More